Celltrion has emerged as the first company to win an EU recommendation for a marketing approval for a biosimilar to Genentech/Novartis’s Xolair (omalizumab), setting up a potential near-term launch with key Xolair compound and formulation patents having already expired or imminently about to run their course.
The Korean firm’s Omlyclo (omalizumab) 75mg and 150mg solution for injection in pre-filled syringe biosimilar has received a positive opinion...






